Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial (vol 395, pg 1278, 2020)

首页> 外文期刊>The Lancet >Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial (vol 395, pg 1278, 2020)

【24h】

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial (vol 395, pg 1278, 2020)

机译：Acalabrutinib有或没有obInutuzumab与氯镁脂和obinutuzumab治疗 - 幼稚慢性淋巴细胞白血病（升高Tn）：随机，受控，第3阶段试验（Vol 395，PG 1278,2020）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2020年第10238期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献

1. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial (vol 395, pg 1278, 2020) [J] . The Lancet . 2020,第10238期

机译：Acalabrutinib有或没有obInutuzumab与氯镁脂和obinutuzumab治疗 - 幼稚慢性淋巴细胞白血病（升高Tn）：随机，受控，第3阶段试验（Vol 395，PG 1278,2020）
2. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial (vol 20, pg 43, 2019) [J] . Moreno C., Greil R., Demirkan F. The lancet oncology . 2019,第1期

机译：Ibrutinib Plus Obinutuzumab与氯苯脲加上Obinutuzumab在慢性淋巴细胞白血病的一线治疗中（亮起）：多期，随机，开放标签，第3阶段试验（Vol 20，PG 43,2019）
3. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial [J] . Moreno Carol, Greil Richard, Demirkan Fatih, The lancet oncology . 2019,第1期

机译：Ibrutinib Plus obinutuzumab与氯苯脲加上obInutuzumab在一线治疗慢性淋巴细胞白血病（照明）：多期，随机，开放标签，第3阶段试验
4. A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma [O] . Alessandra Tedeschi, Richard Greil, Fatih Demirkan, 2020

机译：先前未接受治疗的慢性淋巴细胞性白血病或小淋巴细胞淋巴瘤患者中单药依鲁替尼与苯丁酸氮芥-奥比妥单抗的交叉试验比较
5. A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma [O] . Alessandra Tedeschi, Richard Greil, Fatih Demirkan, 2019

机译：单孕伊布洛替尼与氯蛋白-Obutuzumab在以前未经处理的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者中的交叉试验比较

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial (vol 395, pg 1278, 2020)

著录项

相似文献

相关主题

期刊订阅